SA
Go ProLog In
IFRX
OverviewIntelligenceChart
Q3 2026 EPS Estimate
$-0.13
Reports before open
Revenue Estimate
$6,500

Analyst Sentiment

Wall St. Consensus
Buy
16 analysts·Moderate coverage
70
Score
13 Buy (81%)2 Hold (13%)1 Sell (6%)
Rating Breakdown
Strong Buy
16%
Buy
1275%
Hold
213%
Sell
16%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$2.00
-19.0%
Consensus
$5.50
+122.7%
Bull
$9.00
+264.4%
12-Month Target Range16 analysts
$2.00$5.50$9.00
Current $2.47Consensus
Current Price
$2.47
Upside to Consensus
$3.03

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

No analyst estimates available

Earnings Surprises

Earnings surprise history unavailable.

Recent Analyst Actions

May 13, 2026Raymond James
InflaRx upgraded to Strong Buy from Outperform at Raymond James
Target:$9.00
+254.1%from $2.54
Dec 3, 2025Leerink Partners
InflaRx downgraded to Market Perform from Outperform at Leerink
Target:$2.00
+101.2%from $0.99
May 29, 2025Raymond James
InflaRx downgraded to Outperform from Strong Buy at Raymond James
Target:$2.00
+135.3%from $0.85
Jan 6, 2023H.C. Wainwright
HC Wainwright & Co. Maintains Buy on InflaRx, Lowers Price Target to $6
Target:$6.00
+105.5%from $2.92

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance